<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725855</url>
  </required_header>
  <id_info>
    <org_study_id>MEM 3454-102</org_study_id>
    <nct_id>NCT00725855</nct_id>
  </id_info>
  <brief_title>A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients</brief_title>
  <acronym>P50</acronym>
  <official_title>A Single-Center, Double-Blind, Placebo-Controlled, Randomized Blocks Study Investigating the Effect of 4 Dosages (1 mg, 5 mg, 15 mg, 50 mg) of MEM 3454 on P50 Sensory Gating and Mismatch Negativity (MMN) in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memory Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memory Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of nicotinic alpha-7 MEM 3454 on P50
      sensory gating in patients with Schizophrenia. The hypothesis is that MEM 3454 will normalize
      the P50 ratio.

      Data produced in this study will provide useful information regarding the value of P50 as an
      efficacy biomarker, and provide evidence for the optimal dosing of MEM 3454 for additional
      P50 studies.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the utility of P50 sensory gating as an efficacy biomarker for nicotinic alpha-7 agonist such as MEM 3454.</measure>
    <time_frame>Pre-dosing and Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Investigate the safety and tolerability of MEM 3454 compared with placebo</measure>
    <time_frame>all time points</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Determine whether MMN correlates with P50.</measure>
    <time_frame>Pre-dose and day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEM 3454</intervention_name>
    <description>1 mg dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEM 3454</intervention_name>
    <description>5 mg dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEM 3454</intervention_name>
    <description>15 mg dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEM 3454</intervention_name>
    <description>50 mg dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MEM 3454</intervention_name>
    <description>Placebo dose</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Male or female subjects between 18and 55 years of age.

          -  2. Fluent in English, even if English is not the primary language.

          -  3. Able to provide informed consent.

          -  4. DSM IV-R primary diagnosis of schizophrenia (any subtype), assessed using a
             structured diagnostic interview (SCID CT).

          -  5. Few or no extra-pyramidal symptoms(EPS)at screening,defined as SAS &lt; 6.

          -  6. Negative urine drug screen (UDS).

          -  7. Negative cotinine test.

          -  8. Clinically stable, as judged by the investigator, and in a non-acute phase for at
             least 12 weeks. At least one month on the same dose of antipsychotic medication.

        Exclusion Criteria:

          -  Current risk of suicide, or history of suicidal behavior within the last 6 months.

          -  Hospitalized for psychiatric symptoms in the past 3 months.

          -  Other psychiatric diagnoses.

          -  Substance abuse/dependence (other than nicotine or caffeine) within the last 6 months
             according to the SCID-CT.

          -  Currently smoking, nicotine replacement therapy, smoking cessation medications or
             remedies, including Varenicline (Chantix).

          -  Any medical condition, as judged by the Investigator, which may interfere with the
             subjects' participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Olincy, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Olincy, MD,</last_name>
    <phone>303-315-5046</phone>
    <email>ann.olincy@uchsc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Olincy, MD</last_name>
      <phone>303-315-5046</phone>
      <email>ann.olincy@uchsc.edu</email>
    </contact>
    <investigator>
      <last_name>Ann Olincy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Braff DL, Light GA, Swerdlow NR. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry. 2007 May 15;61(10):1204-7. Epub 2006 Dec 8.</citation>
    <PMID>17161386</PMID>
  </reference>
  <reference>
    <citation>Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006 Jun;63(6):630-8.</citation>
    <PMID>16754836</PMID>
  </reference>
  <reference>
    <citation>Simosky JK, Stevens KE, Freedman R. Nicotinic agonists and psychosis. Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):149-62. Review.</citation>
    <PMID>12769624</PMID>
  </reference>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2008</study_first_submitted>
  <study_first_submitted_qc>July 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2008</study_first_posted>
  <last_update_submitted>July 30, 2008</last_update_submitted>
  <last_update_submitted_qc>July 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Abdul Abdullah, MD, Project Medical Director</name_title>
    <organization>Memory Pharmaceuticals Corp.</organization>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>P50 Sensory Gating</keyword>
  <keyword>Mismatched Negativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

